Next Article in Journal
Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice
Next Article in Special Issue
Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination
Previous Article in Journal
Recent Developments in Vaccines for Bovine Mycoplasmoses Caused by Mycoplasma bovis and Mycoplasma mycoides subsp. mycoides
Previous Article in Special Issue
Prevalence of Anti-SARS-CoV-2 Antibodies in Poznań, Poland, after the First Wave of the COVID-19 Pandemic
 
 
Review

Article Versions Notes

Vaccines 2021, 9(6), 550; https://doi.org/10.3390/vaccines9060550
Action Date Notes Link
article pdf uploaded. 24 May 2021 15:26 CEST Version of Record https://www.mdpi.com/2076-393X/9/6/550/pdf-vor
article xml file uploaded 25 May 2021 05:43 CEST Original file -
article xml uploaded. 25 May 2021 05:43 CEST Update https://www.mdpi.com/2076-393X/9/6/550/xml
article pdf uploaded. 25 May 2021 05:43 CEST Updated version of record https://www.mdpi.com/2076-393X/9/6/550/pdf
article html file updated 25 May 2021 05:44 CEST Original file -
article html file updated 25 May 2021 05:44 CEST Update -
article html file updated 26 July 2022 21:05 CEST Update https://www.mdpi.com/2076-393X/9/6/550/html
Back to TopTop